eigerbioadmin

»eigerbioadmin

About eigerbioadmin

This author has not yet filled in any details.
So far eigerbioadmin has created 146 blog entries.
6 02, 2019

Eiger BioPharmaceuticals Announces Patent Protection for Lonafarnib Boosted with Ritonavir for Treatment of Hepatitis Delta Virus Infection in Europe and Japan

2019-02-06T18:39:19+00:00

Eiger BioPharmaceuticals Announces Patent Protection for Lonafarnib Boosted with Ritonavir for Treatment of Hepatitis Delta Virus Infection in Europe and Japan Expanded Patent Portfolio Now Includes U.S., Europe and Japan PALO ALTO, Calif., February 6, 2019 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare [...]

Eiger BioPharmaceuticals Announces Patent Protection for Lonafarnib Boosted with Ritonavir for Treatment of Hepatitis Delta Virus Infection in Europe and Japan2019-02-06T18:39:19+00:00
4 02, 2019

Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study of Avexitide in Post-Bariatric Hypoglycemia (PBH) at Upcoming Endocrine Society (ENDO) Meeting 2019 in New Orleans

2019-02-04T15:27:59+00:00

Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study of Avexitide in Post-Bariatric Hypoglycemia (PBH) at Upcoming Endocrine Society (ENDO) Meeting 2019 in New Orleans PALO ALTO, Calif., February 4, 2019 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced an oral presentation has [...]

Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study of Avexitide in Post-Bariatric Hypoglycemia (PBH) at Upcoming Endocrine Society (ENDO) Meeting 2019 in New Orleans2019-02-04T15:27:59+00:00
7 01, 2019

Eiger BioPharmaceuticals Appoints Regulatory Expert and Industry Veteran Christine Murray, MS, RAC to its Board of Directors

2019-01-07T15:50:15+00:00

Eiger BioPharmaceuticals Appoints Regulatory Expert and Industry Veteran Christine Murray, MS, RAC to its Board of Directors PALO ALTO, Calif., January 7, 2019 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare and ultra-rare diseases, announced today the appointment of Christine Murray, MS, RAC to its Board of Directors. [...]

Eiger BioPharmaceuticals Appoints Regulatory Expert and Industry Veteran Christine Murray, MS, RAC to its Board of Directors2019-01-07T15:50:15+00:00
19 12, 2018

Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib in Progeria and Progeroid Laminopathies

2018-12-19T14:26:30+00:00

Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib in Progeria and Progeroid Laminopathies Survival Benefit in Children with Progeria Published in JAMA 2018 NDA Filing Planned in 2019 PALO ALTO, Calif., December 19, 2018 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare [...]

Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib in Progeria and Progeroid Laminopathies2018-12-19T14:26:30+00:00
18 12, 2018

Eiger Announces PRIME Designation Granted by European Medicines Agency for Lonafarnib for Treatment of Hepatitis Delta Virus Infection

2018-12-18T15:15:54+00:00

Eiger Announces PRIME Designation Granted by European Medicines Agency for Lonafarnib for Treatment of Hepatitis Delta Virus Infection Phase 3 HDV “D-LIVR” International Study Initiating PALO ALTO, Calif., December 18, 2018 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced the European [...]

Eiger Announces PRIME Designation Granted by European Medicines Agency for Lonafarnib for Treatment of Hepatitis Delta Virus Infection2018-12-18T15:15:54+00:00
17 12, 2018

Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib for Treatment of Hepatitis Delta Virus (HDV) Infection

2018-12-17T17:00:35+00:00

Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib for Treatment of Hepatitis Delta Virus (HDV) Infection - Phase 3 HDV “D-LIVR” International Study Initiating PALO ALTO, Calif., December 17, 2018 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that the [...]

Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib for Treatment of Hepatitis Delta Virus (HDV) Infection2018-12-17T17:00:35+00:00
11 12, 2018

Eiger BioPharmaceuticals Reports on 2018 R&D Day

2018-12-11T21:30:44+00:00

Eiger BioPharmaceuticals Reports on 2018 R&D Day Late Stage Rare and Ultra-Rare Disease Pipeline Advancing >$100M in Cash Available to Achieve Key Milestones PALO ALTO, Calif., December 11, 2018 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced recent accomplishments reported at [...]

Eiger BioPharmaceuticals Reports on 2018 R&D Day2018-12-11T21:30:44+00:00
4 12, 2018

Eiger BioPharmaceuticals to Host R&D Day in New York City

2018-12-04T14:51:54+00:00

Eiger BioPharmaceuticals to Host R&D Day in New York City PALO ALTO, Calif., December 4, 2018 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced it will host an R&D Day on December 11, 2018 from 12:00 PM to 2:30 PM EST at [...]

Eiger BioPharmaceuticals to Host R&D Day in New York City2018-12-04T14:51:54+00:00
3 12, 2018

Eiger BioPharmaceuticals Announces FDA Acceptance of IND Application for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies

2018-12-03T15:51:26+00:00

Eiger BioPharmaceuticals Announces FDA Acceptance of IND Application for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies Plans to File NDA in 2019PALO ALTO, Calif., December 3, 2018 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that the U.S. Food and [...]

Eiger BioPharmaceuticals Announces FDA Acceptance of IND Application for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies2018-12-03T15:51:26+00:00
3 12, 2018

Eiger BioPharmaceuticals Announces the Appointment of Sri Ryali as Chief Financial Officer

2018-12-04T11:27:49+00:00

Eiger BioPharmaceuticals Announces the Appointment of Sri Ryali as Chief Financial Officer PALO ALTO, Calif., December 3, 2018 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced the appointment of Sri Ryali as the company’s Chief Financial Officer.  Mr. Ryali brings over fifteen [...]

Eiger BioPharmaceuticals Announces the Appointment of Sri Ryali as Chief Financial Officer2018-12-04T11:27:49+00:00